Stock LUCD LUCID DIAGNOSTICS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Lucid Diagnostics Inc.

Equities

LUCD

US54948X1090

Market Closed - Nasdaq
Other stock markets
 01:30:00 27/04/2024 am IST 		5-day change 1st Jan Change
0.6831 USD +1.94% Intraday chart for Lucid Diagnostics Inc. -14.24% -51.55%
27/03 Cantor Fitzgerald Trims Price Target on Lucid Diagnostics to $3 From $3.80, Maintains Overweight Rating MT
26/03 Transcript : Lucid Diagnostics Inc., Q4 2023 Earnings Call, Mar 26, 2024

Summary

  • On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
  • From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

  • According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Weaknesses

  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • Low profitability weakens the company.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
  • For the past year, analysts have significantly revised downwards their profit estimates.
  • Over the past four months, analysts' average price target has been revised downwards significantly.
  • The average consensus view of analysts covering the stock has deteriorated over the past four months.
  • Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
  • The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
  • Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Sector: Medical Equipment, Supplies & Distribution

1st Jan change Capi. Investor Rating ESG Refinitiv
LUCID DIAGNOSTICS INC. Stock Lucid Diagnostics Inc.
-51.55% 32.96M -
SHOCKWAVE MEDICAL, INC. Stock Shockwave Medical, Inc.
+73.17% 12.38B
B-
PENUMBRA, INC. Stock Penumbra, Inc.
-18.74% 7.92B
C+
MASIMO CORPORATION Stock Masimo Corporation
+16.15% 7.2B
C-
GETINGE AB Stock Getinge AB
+4.81% 5.84B
B
JIANGSU YUYUE MEDICAL EQUIPMENT & SUPPLY CO., LTD. Stock Jiangsu Yuyue Medical Equipment & Supply Co., Ltd.
+5.99% 5.07B
D+
APT MEDICAL INC. Stock APT Medical Inc.
+27.07% 4.53B -
ASAHI INTECC CO., LTD. Stock Asahi Intecc Co., Ltd.
-21.67% 3.88B
B-
INARI MEDICAL, INC. Stock Inari Medical, Inc.
-40.82% 2.23B
C
SKAN GROUP AG Stock SKAN Group AG
+1.49% 2.02B -
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
-
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. LUCD Stock
  4. Ratings Lucid Diagnostics Inc.